Counterpart Health Names David Tsay M.D., Ph.D as Chief Medical Officer
Counterpart Health, a subsidiary of Clover Health (Nasdaq: CLOV), has appointed David Tsay M.D., Ph.D as Chief Medical Officer (CMO). Dr. Tsay will advance Counterpart's clinical strategy and product roadmap for Counterpart Assistant, an AI-powered physician enablement platform. With over two decades of experience in health technology and clinical innovation, Dr. Tsay previously held leadership roles at Cue Health, Apple, and New York-Presbyterian.
Counterpart Health's CEO, Conrad Wai, expressed confidence in Dr. Tsay's ability to accelerate the company's expansion into value-based healthcare networks. Dr. Tsay highlighted Counterpart Assistant as an innovative solution for providers looking to deliver value-based care. The platform aims to reduce the total cost of care in value-based models through advanced chronic disease management.
Counterpart Health, una consociata di Clover Health (Nasdaq: CLOV), ha nominato David Tsay M.D., Ph.D come Chief Medical Officer (CMO). Il Dr. Tsay avanzer脿 la strategia clinica di Counterpart e la roadmap del prodotto per Counterpart Assistant, una piattaforma di abilitazione per i medici basata sull'IA. Con oltre vent'anni di esperienza nella tecnologia sanitaria e innovazione clinica, il Dr. Tsay ha ricoperto ruoli di leadership in Cue Health, Apple e New York-Presbyterian.
Il CEO di Counterpart Health, Conrad Wai, ha espresso fiducia nella capacit脿 del Dr. Tsay di accelerare l'espansione dell'azienda nelle reti sanitarie basate sul valore. Il Dr. Tsay ha evidenziato Counterpart Assistant come una soluzione innovativa per i fornitori che cercano di offrire assistenza basata sul valore. La piattaforma mira a ridurre il costo totale delle cure nei modelli basati sul valore attraverso una gestione avanzata delle malattie croniche.
Counterpart Health, una subsidiaria de Clover Health (Nasdaq: CLOV), ha nombrado al Dr. David Tsay M.D., Ph.D como Director M茅dico (CMO). El Dr. Tsay impulsar谩 la estrategia cl铆nica de Counterpart y la hoja de ruta del producto para Counterpart Assistant, una plataforma de habilitaci贸n para m茅dicos impulsada por IA. Con m谩s de dos d茅cadas de experiencia en tecnolog铆a de salud e innovaci贸n cl铆nica, el Dr. Tsay ocup贸 roles de liderazgo en Cue Health, Apple y New York-Presbyterian.
El CEO de Counterpart Health, Conrad Wai, expres贸 confianza en la capacidad del Dr. Tsay para acelerar la expansi贸n de la empresa en redes de atenci贸n m茅dica basadas en el valor. El Dr. Tsay destac贸 a Counterpart Assistant como una soluci贸n innovadora para los proveedores que buscan ofrecer atenci贸n basada en el valor. La plataforma tiene como objetivo reducir el costo total de la atenci贸n en modelos basados en el valor a trav茅s de una gesti贸n avanzada de enfermedades cr贸nicas.
旃挫毚韯绊寣韸� 項姢电� 韥措氩� 項姢 (Nasdaq: CLOV)鞚� 鞛愴殞靷 David Tsay M.D., Ph.D毳� 斓滉碃 鞚橂 毂呾瀯鞛� (CMO)搿� 鞛勲獏頄堨姷雼堧嫟. Tsay 氚曥偓电� Counterpart Assistant鞚� 鞛勳儊 鞝勲灥 氚� 鞝滍拡 搿滊摐毵奠潉 氚滌爠鞁滍偓 瓴冹瀰雼堧嫟. 20雲� 鞚挫儊鞚� 瓯搓皶 旮办垹 氚� 鞛勳儊 順侅嫚 瓴巾棙鞚� 氤挫湢頃橁碃 鞛埖鐢 Tsay 氚曥偓电� Cue Health, Apple, New York-Presbyterian鞐愳劀 毽崝鞁� 鞐暊鞚� 靾橅枆頄堨姷雼堧嫟.
旃挫毚韯绊寣韸� 項姢鞚� CEO鞚� Conrad Wai电� Tsay 氚曥偓臧� 臧�旃� 旮半皹 鞚橂 雱ろ姼鞗岉伂搿滌潣 須岇偓 頇曥灔鞚� 臧�靻嶍檾頃� 電ル牓鞚� 臧�歆�瓿� 鞛堧嫟瓿� 頇曥嫚鞚� 響滊獏頄堨姷雼堧嫟. Tsay 氚曥偓电� 鞝滉车鞛愱皜 臧�旃� 旮半皹 旃橂毳� 鞝滉车頃橂牑电� 順侅嫚鞝侅澑 靻旊（靺橃溂搿� Counterpart Assistant毳� 臧曥“頄堨姷雼堧嫟. 鞚� 頂岆灚韽检潃 毵岇劚 歆堩櫂 甏�毽ゼ 韱淀暣 臧�旃� 旮半皹 氇嵏鞐愳劀 齑� 旃橂 牍勳毄鞚� 欷勳澊电� 瓴冹潉 氇╉憸搿� 頃╇媹雼�.
Counterpart Health, une filiale de Clover Health (Nasdaq: CLOV), a nomm茅 David Tsay M.D., Ph.D au poste de Directeur M茅dical (CMO). Le Dr. Tsay fera avancer la strat茅gie clinique de Counterpart et la feuille de route pour Counterpart Assistant, une plateforme d'habilitation des m茅decins powered by IA. Fort de plus de 20 ans d'exp茅rience en technologie de la sant茅 et innovation clinique, le Dr. Tsay a pr茅c茅demment occup茅 des postes de direction chez Cue Health, Apple et New York-Presbyterian.
Le PDG de Counterpart Health, Conrad Wai, a exprim茅 sa confiance dans la capacit茅 du Dr. Tsay 脿 acc茅l茅rer l'expansion de l'entreprise dans les r茅seaux de soins de sant茅 bas茅s sur la valeur. Le Dr. Tsay a soulign茅 Counterpart Assistant comme une solution innovante pour les prestataires cherchant 脿 offrir des soins bas茅s sur la valeur. La plateforme vise 脿 r茅duire le co没t total des soins dans les mod猫les bas茅s sur la valeur gr芒ce 脿 une gestion avanc茅e des maladies chroniques.
Counterpart Health, eine Tochtergesellschaft von Clover Health (Nasdaq: CLOV), hat David Tsay M.D., Ph.D zum Chief Medical Officer (CMO) ernannt. Dr. Tsay wird die klinische Strategie von Counterpart und die Produkt-Roadmap f眉r Counterpart Assistant, eine KI-gest眉tzte Plattform zur Unterst眉tzung von 脛rzten, vorantreiben. Mit 眉ber zwei Jahrzehnten Erfahrung in der Gesundheitstechnologie und klinischen Innovationen hatte Dr. Tsay zuvor F眉hrungspositionen bei Cue Health, Apple und New York-Presbyterian inne.
Der CEO von Counterpart Health, Conrad Wai, 盲u脽erte Vertrauen in die F盲higkeit von Dr. Tsay, die Expansion des Unternehmens in wertbasierte Gesundheitsnetze zu beschleunigen. Dr. Tsay hob Counterpart Assistant als innovative L枚sung f眉r Anbieter hervor, die wertbasierte Pflege anbieten m枚chten. Die Plattform zielt darauf ab, die Gesamtkosten der Pflege in wertbasierten Modellen durch ein fortschrittliches Management chronischer Krankheiten zu senken.
- Appointment of David Tsay M.D., Ph.D as Chief Medical Officer, bringing expertise in AI, digital health, and clinical innovation
- Potential for accelerated expansion into value-based healthcare networks and systems nationwide
- Counterpart Assistant platform designed to help reduce total cost of care in value-based care models
- None.
Dr. Tsay Brings Unique Expertise in AI, Digital Health, and Clinical Innovation to Counterpart Health
FRANKLIN, Tenn., Oct. 08, 2024 (GLOBE NEWSWIRE) -- . (鈥淐ounterpart鈥�), a leading AI-powered physician enablement platform, today announced the appointment of David Tsay M.D., Ph.D as Chief Medical Officer (CMO). Dr. Tsay will play a key role in advancing Counterpart鈥檚 clinical strategy and product roadmap for Counterpart Assistant, the company鈥檚 proprietary AI-powered physician enablement software platform that empowers providers to deliver high-quality, cost-effective care. Counterpart is a subsidiary of Clover Health Investments, Corp. (Nasdaq: CLOV) (鈥淐lover Health鈥�).
David Tsay is a distinguished physician executive with deep expertise and over two decades of experience in health technology, product development, and clinical innovation. Prior to Counterpart, Dr. Tsay served in clinical leadership roles in the technology industry, most recently as Chief Medical Officer at Cue Health where he led regulatory, clinical, and medical affairs. Before Cue Health, Dr. Tsay led the clinical team for digital health medical device products at Apple. Prior to Apple, Dr. Tsay served as Associate Chief Transformation Officer at New York-Presbyterian (NYP), one of the nation's most comprehensive academic healthcare delivery systems, leading digital transformation initiatives for NYP in artificial intelligence, automation, and digital web/mobile technologies.
Dr. Tsay received his BA in Computer Science and Physics from Columbia University College, M.D., Ph.D degrees from Columbia University College of Physicians and Surgeons, and is board certified in internal medicine and cardiology.
"Counterpart Health is built on groundbreaking technology that empowers physicians to excel in value-based care, particularly in the management of chronic diseases," said Conrad Wai, CEO of Counterpart Health. "Dr. Tsay鈥檚 world-class expertise in clinical innovation and health technology makes him a valuable addition to our team. I鈥檓 confident that his leadership will be instrumental as we accelerate our expansion into more value-based healthcare networks and systems nationwide."
"I鈥檝e had the privilege of contributing to world-class institutions like Apple and NewYork-Presbyterian, which operate at the critical crossroads of healthcare and technology. Counterpart attracted me because it offers one of the most compelling solutions I鈥檝e encountered," Tsay remarked. "With an increasing number of providers looking to deliver value-based care, Counterpart Assistant provides an innovative technology designed specifically for this purpose. I look forward to working alongside this skilled team in its mission to help improve providers鈥� and patients鈥� lives."
For companies interested in learning more about how Counterpart can reduce the total cost of care in value-based care models through advanced chronic disease management, visit .
About Counterpart Health
, a subsidiary of Clover Health Investments, Corp., or Clover Health, is a leading AI-powered physician enablement platform. Counterpart Health鈥檚 flagship software platform, Counterpart Assistant, was incubated by Clover Health as Clover Assistant and has helped improve plan performance and clinical outcomes for Medicare members through proprietary AI technology. Counterpart Health extends the benefits of the data-driven technology platform outside of Clover Health鈥檚 Medicare Advantage plan to a wider audience, to enable enhanced patient outcomes and reduced healthcare costs nationwide. Clover Health has published data demonstrating the technology鈥檚 impact on , as well as the earlier identification and management of and .
Press Contact:
Andrew Still-Baxter
press@cloverhealth.com
Investor Relations Contact:
Ryan Schmidt
investors@cloverhealth.com
FAQ
Who is the new Chief Medical Officer of Counterpart Health?
What is Counterpart Health's relationship to Clover Health (CLOV)?
What is Counterpart Assistant?
How does Counterpart Health aim to impact value-based care?
